Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.41 |
| ▸ | CDC7 | O00311 | 4/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902124 | 0.90 | CLK1 (0.49) | CLK1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL4902489 | 0.88 | KDM4E (0.59) | CLK1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL4894356 | 0.82 | HPGD (0.58) | CLK1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL4900837 | 0.77 | KDM4E (0.61) | KDM4EMEN1KMT2ARXFP1CYP1A2 | |
| SCHEMBL4901399 | 0.76 | KAT8 (0.52) | CLK1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL12969724 | 0.72 | LIMK1 (0.68) | CLK1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL4901029 | 0.71 | HPGD (0.60) | KDM4EMEN1KMT2ARXFP1MAPT | |
| SCHEMBL4899938 | 0.69 | LIMK1 (0.66) | CLK1KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL4895355 | 0.69 | MAPT (0.61) | KDM4EMEN1KMT2ARXFP1CYP1A2 | |
| Bromide SCHEMBL4901715 | 0.68 | MAPT (0.60) | KDM4EMEN1KMT2ARXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | CLK1 3223/4885KDM4E 3715/4885MEN1 3677/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | CLK1 3223/4885KDM4E 3715/4885MEN1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.